Mifepristone

225 interactions 13 explained in plain English
Also sold as: Korlym Mifeprex
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Major

Mifepristone Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Mifepristone Omeprazole Gastrobim Explained Increased CYP3A4 substrate exposure Details Mifepristone Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Mifepristone Sertraline Explained Increased sertraline exposure and an increased risk of QT interval prolongation Details Mifepristone Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Mifepristone Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Mifepristone Alpelisib Piqray Increased CYP3A4 substrate exposure Details Mifepristone Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Mifepristone Apixaban Eliquis Explained Increased apixaban exposure and an increased risk of bleeding Details Mifepristone Arsenic Trioxide Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Mifepristone Aripiprazole Injection Abilify Increased ARIPiprazole exposure and an increased risk of QT interval prolongation Details Mifepristone Arsenic Trioxide Injection Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Mifepristone Asciminib Scemblix Increased miFEPRIStone exposure and an increased asciminib exposure Details Mifepristone Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Mifepristone Atogepant Qulipta Increased atogepant exposure Details Mifepristone Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Mifepristone Avatrombopag Doptelet Increased CYP3A4 substrate exposure Details Mifepristone Azithromycin AzaSite Increased miFEPRIStone exposure and an increased risk of QT interval prolongation Details Mifepristone Belumosudil Rezurock Explained Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Bicalutamide Casodex Increased miFEPRIStone exposure Details Mifepristone Atorvastatin Atorvaliq Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Mifepristone Abiraterone Abirtega Increased CYP3A4 substrate exposure Details Mifepristone Alfuzosin UroXatral Increased CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Mifepristone Amlodipine Amvaz® Increased miFEPRIStone exposure, an increased amLODIPine exposure and an increased risk of hypotension and edema Details Mifepristone Anagrelide Agrylin Increased risk of QT interval prolongation Details Mifepristone Avanafil Stendra Increased CYP3A4 substrate exposure Details Mifepristone Bedaquiline Sirturo Increased bedaquiline exposure and an increased risk of QT interval prolongation Details Mifepristone Brexpiprazole Rexulti Increased brexpiprazole exposure Details Mifepristone Brodalumab Injection Siliq Increased miFEPRIStone exposure Details Mifepristone Cabozantinib Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Mifepristone Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Mifepristone Capmatinib Tabrecta Increased CYP3A4 substrate exposure Details Mifepristone Chloroquine Aralen® An increased risk of QT interval prolongation Details Mifepristone Clotrimazole Aardora Anti-Fungal Maximum Strength Increased miFEPRIStone exposure Details Mifepristone Clotrimazole Lozenge Mycelex® Increased miFEPRIStone exposure Details Mifepristone Clotrimazole Topical Cruex Antifungal Increased miFEPRIStone exposure Details Mifepristone Clotrimazole Vaginal Gyne-Lotrimin 3® Cream Increased miFEPRIStone exposure Details Mifepristone Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Mifepristone Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.